TP53 and hyperlipidemia: Phadwal and coworkers found that in vitro MET promotes the autophagic degradation of RUNX2, thus preventing calcification in a dose-dependent manner (20), while in another study, pre-treatment with in vivo or in vitro MET was able to mitigate hyperlipidemia-associated accumulation of vascular calcifications by enhancing ferroptosis and to enhance the antioxidative capacity of VSMCs via p53 and Nrf2 signaling (45).